INTRODUCTION {#sec1-1}
============

Among all the malignancies, oral cancer is the tenth most common cancer in the world with a marked geographic difference in occurrence and hence remains a serious oral health problem worldwide.\[[@ref1]\] The highest rates in the world for oral cancer are found in France, the Indian subcontinent, Brazil and Central/Eastern Europe.\[[@ref2]\] The common occurrence among Indian population is attributed to the well-established association of oral cancer with betel-quid chewing.\[[@ref3]\] Oral cancer has one of the lowest survival rates of 30%--80%, within a 5-year period.\[[@ref4][@ref5][@ref6][@ref7]\] The WHO reported oral cancer as having one of the highest mortality ratios among all malignancies,\[[@ref5]\] due to delayed diagnosis and the surgical treatment causing facial disfigurement, impaired speech and malnutrition.\[[@ref8]\] The absence of a reliable method for early diagnosis of oral cancer is responsible for the delay in diagnosis and thus poor prognosis. Even a thorough clinical examination cannot reliably identify early malignancies as they might not be clinically palpable and might resemble the surrounding normal mucosa in color. Furthermore, early lesions might resemble reactive or inflammatory condition. Thus, identifying a clinically suspicious or undetectable lesion through some diagnostic adjunct has gained importance, whereby diagnosis can be confirmed by biopsy at an earlier stage.\[[@ref9]\]

Noninvasive screening tools such as toluidine blue allow a clinician to more reliably evaluate the high-risk sites in the oral cavity. The newer modalities such as chemiluminescence use wavelengths that reveal obvious differences in the color of suspected lesions compared to the surrounding healthy tissue. This offers the clinician the potential to identify dysplastic cells in earlier stages and to discover unseen borders. These diagnostic adjuncts aid in diagnosing suspicious areas in premalignant lesions, offering a promise in terms of early diagnosis and thereby instituting early treatment. Thus, the present study aims to compare these screening methods to find out their efficacy in early detection of carcinoma and also to compare these methods with gold standard biopsy.

METHODS {#sec1-2}
=======

The study design involved screening of clinically visible oral potentially malignant disorders and malignant lesions with the conventional toluidine blue vital staining and the newer chemiluminescence technique. This study was approved by the Institutional Ethical committee, and all the guidelines given in the Declaration of Helsinki were followed.

Forty-two individuals (37 males and 5 females), between 21 and 60 years of age, reporting to the Department of Oral Pathology and Microbiology, presenting with the clinically evident oral potentially malignant and malignant pathologies were included in the study after obtaining informed consent.

Demographic data were collected, suspicious lesions were examined conventionally under incandescent light and the findings were recorded. This was followed by chemiluminescence examination where the patient was asked to rinse oral cavity by 1% acetic acid solution for 1 min. Room lights were dimmed, the oral cavity was examined under chemiluminescence light (Vizilite) and the findings were recorded. Mucosa which appeared as decreased blue or dark was recorded as negative finding, and the mucosa appearing as improved "aceto-white" was considered a positive finding.

This was followed by examination with 1% toluidine blue where all visualized lesions were again swabbed with 1% acetic acid followed by local application of toluidine blue (Mashberg\'s recommendation) with a presoaked swab for 2 min. The patient was then asked to rinse the oral cavity by 1% acetic acid to remove any extra toluidine blue. Retention of toluidine blue was recorded for each lesion under standard incandescent light as positive or negative. Special care was taken to remove mechanical retention of the dye to reduce false-positive results. After rinsing the mouth with 1% acetic acid, dye from the retention areas was again wiped with cotton bud soaked in 1% acetic acid.

Biopsy and histopathological analysis of the tissues were performed. The paraffin-embedded specimens were cut into 3--4 μm thick sections and stained with hematoxylin-eosin. The tissues were analyzed and were classified as negative (acanthosis, inflammatory lesions), positive which included dysplasia (subdivided into mild dysplasia, moderate dysplasia, severe dysplasia and carcinoma *in situ*), oral lichen planus, oral submucous fibrosis, proliferative verrucous leukoplakia and invasive carcinoma (squamous cell carcinoma \[SCC\] and verrucous carcinoma). The definition of invasive carcinoma was based on the detection of infiltrative growth patterns for individual malignant cells or glands. Results from biopsy were considered as gold standard of diagnosis.

The data obtained were statistically analyzed. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value for the chemiluminescent technique and toluidine blue were calculated using the UK Centre for Evidence-Based Medicine online calculator for diagnostic test. Sensitivity, specificity, accuracy, PPV and negative predictive value were calculated using the following formulae:

Sensitivity = (true positives/\[true positive + false negative\]) ×100Specificity = (true negatives/\[true negative + false positive\]) ×100Accuracy = sensitivity + specificityPredictive value for a positive result (PV+) = (true positive/\[true positive + false positive\]) ×100Predictive value for a negative result (PV−) = (true negative/\[true negative + false negative\]) ×100.

The SPSS 20.0 software package for Macintosh (IBM, Armonk, NY, USA) was used for data analysis.

RESULTS {#sec1-3}
=======

Clinically, leukoplakia was the most common finding with 23 cases (54.8%) either alone or in combination with other oral potentially malignant disorders, followed by oral submucous fibrosis (OSMF) and rest presenting as oral lichen planus, tobacco pouch keratosis, verrucous lesions and oral carcinoma. Chemiluminescence diagnosed 18 dysplasia (90%), 3 carcinomas *in situ* (100%), 4 (100%) cases of SCC and 2 (100%) cases of verrucous carcinoma to be positive giving true-positive results \[[Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}\]. Toluidine blue diagnosed 10 dysplasia (50%), 2 carcinomas *in situ* (66%), 4 SCCs (100%), 2 verrucous carcinomas (100%) and 1 proliferative verrucous leukoplakia (100%) cases to be positive giving true-positive results \[[Figure 2](#F2){ref-type="fig"}\]. Few false positive and few false negative were also seen \[Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}\]. Toluidine blue provided positive findings in 21 (50%) cases whereas chemiluminescence provided positive findings in 33 (78.6%) cases (*P* = 0.006).

###### 

Correlation between toluidine blue/chemiluminescence positivity and histopathological findings

![](JOMFP-22-442-g001)

![Use of Vizilite as an oral cancer screening method. (a) Activating Vizilite capsule by flexing it, (b) examination of the patient\'s oral cavity with Vizilite, (c) application of toluidine blue stain with cotton bud, (d) removal of mechanical retention of dye with 1% acetic acid](JOMFP-22-442-g002){#F1}

![Use of Vizilite and toluidine blue stain as an oral cancer screening method. (a) Clinically identified leukoplakia on left buccal mucosa under conventional visual examination, (b) Vizilite true positive, (c) toluidine blue true positive, (d) histopathologically moderate epithelial dysplasia (H&E, ×10), (e) clinically identified proliferative verrucous leukoplakia on left buccal mucosa under conventional visual examination, (f) Vizilite false negative, (g) toluidine blue true positive, (h) histopathologically proliferative verrucous leukoplakia (H&E, ×10)](JOMFP-22-442-g003){#F2}

![Use of Vizilite and toluidine blue stain as an oral cancer screening method. (a) Clinically identified nonhomogenous leukoplakia on left buccal mucosa under conventional visual examination, (b) Vizilite true positive, (c) toluidine blue false negative, (d) histopathologically mild epithelial dysplasia (H&E, ×10), (e) clinically identified nonhomogenous leukoplakia on left buccal mucosa under conventional visual examination, (f) Vizilite true positive, (g) toluidine blue true positive, (h) histopathologically carcinoma *in situ* (H&E, ×10)](JOMFP-22-442-g004){#F3}

![(a) Clinically identified Nonhomogenous leukoplakia on left buccal mucosa under conventional visual examination, (b) Vizilite True Positive, (c) Toluidine blue True positive, (d) Histopathologically Oral squamous cell carcinoma (H&E 10X)](JOMFP-22-442-g005){#F4}

Histopathologically, dysplasia was the most common entity (in different grades) followed by OSMF. The diagnostic efficacy of both the tools was measured in terms of sensitivity, specificity, PPV and negative predictive value. The toluidine blue test was found to be moderately sensitive with a sensitivity of 63.33%; however, the test was highly specific showing a specificity of 83.33%. The PPV of the test was quite high with a PPV of 90.48%; however, the negative predictive value was very low, i.e., 47.62%.

The Vizilite was found to be highly sensitive with a sensitivity of 90%; however, the test has limited specificity of 50%. The PPV of the test was quite high with a PPV of 81.82%; however, the negative predictive value was just moderate, i.e., 66.67%. Diagnostic agreement between toluidine blue and chemiluminescence was low with a κ = 0.238 (*P* \< 0.05) \[[Table 1](#T1){ref-type="table"}\].

DISCUSSION {#sec1-4}
==========

Literature indicates the poor prognosis of patients with oral SCC, despite advances in management strategies with regard to its treatment. Early diagnosis and institution of the treatment remain the key to improved patient survival;\[[@ref10]\] hence, the present study attempts to illustrate the efficacy of toluidine blue and chemiluminescence in diagnosing oral potentially malignant disorders and oral cancer.

Toluidine blue is a cationic metachromatic dye that stains deoxyribonucleic acid and/or may be retained in intracellular spaces of dysplastic epithelium and clinically may appear as royal blue areas.\[[@ref11]\] Theoretically, dysplastic and malignant cells have higher nucleic acid content than normal, and thus, staining of suspicious lesions with this dye can aid recognition of mucosal changes.\[[@ref12]\] It is one of the most accepted screening tools used since a long time and has even been suggested as an alternative to frozen sections in developing countries.\[[@ref13][@ref14]\] The usefulness and reliability of toluidine blue dye which binds to malignant or dysplastic tissues have been demonstrated in many studies.\[[@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref13][@ref14]\]

In the present study, toluidine blue stained only 50% of dysplasia positive though serious pathologies such as SCC and verrucous carcinoma cases were 100% positive, showing a sensitivity of 63.33% and a specificity of 83.33%, which is consistent with previous findings of Lingen *et al*. in 2008.\[[@ref22]\] In contrast, various investigators have reported higher sensitivity (95%--88.23%) and lower specificity (76.9%--42.4%).\[[@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25]\] In the present study, care was taken to eliminate the mechanical retention of the dye, which was responsible for false-positive results in most of the studies and which may account for the higher sensitivity for carcinoma cases.\[[@ref18][@ref19]\] Missmann *et al*.\[[@ref15]\] and Miller *et al*.\[[@ref16]\] stated that the plausible reason for giving high sensitivity and specificity for malignant lesions and not premalignant lesions could be that toluidine blue appears to stain only 3--4 cell layers deep. Therefore, early invasive SCCs that might be surfaced by intact epithelium, keratinization and not exposed to the oral environment do not take up the stain. The results of our study showed that diagnostic agreement between toluidine blue and histopathology was low although statistically it was a significant association (*P* \< 0.05), which is in agreement with Upadhyay *et al*.\'s observations regarding the questionable reliability of toluidine blue staining due to this high false-positive and false-negative results.\[[@ref26]\] Güneri *et al*. also indicated the confusion regarding the blue color perception in the oral lesions;\[[@ref27]\] hence, the low degree of observer agreement deters the use of toluidine blue as a substitute for histopathology as has been seen in other studies.\[[@ref5][@ref9][@ref16][@ref18]\]

Chemiluminescence (Vizilite) is the other screening test used in the study which has been approved for use in the United States by the Food and Drug Administration since November 2001. Normal epithelium will absorb chemiluminescent light and appear dark, whereas hyperkeratinized or dysplastic lesions appear white. The difference in color could be related to altered epithelial thickness or to the higher density of nuclear content and mitochondrial matrix that preferentially reflects light in the pathological tissues.\[[@ref12]\] Most of the studies have shown that chemiluminescence increases the brightness and margins of oral mucosal white lesions and thus assists in identification of mucosal lesions not considered under conventional visual examination.\[[@ref28][@ref29][@ref30]\]

The present study reveals Vizilite to be highly sensitive (90%) with a limited specificity (50%). The PPV of the test was quite high with a value of 81.82%; however, the negative predictive value was just moderate i.e., 66.67%. Two case--control studies suggested varied opinion regarding accuracy of Vizilite ranging from 18.2% to 80.6%.\[[@ref31][@ref19]\] However, both studies reported sensitivity to be 100% and specificity as low as 0% and 14.2%. Vashisht *et al*. reported sensitivity and specificity of Vizilite to be 95.45% and 84.6%, respectively,\[[@ref20]\] whereas Awan *et al*. reported it to be as 77.3% and 27.8%, respectively.\[[@ref30]\] The results of the present study are consistent with systematic reviews done by Giovannacci *et al*. and Nagi *et al*., who reported sensitivity of Vizilite ranging from 77.1% to 100% and specificity ranging from 0% to 27.8%.\[[@ref32][@ref33]\]

In the present study, the diagnostic agreement between chemiluminescence (Vizilite) and histopathology was average with a Kappa value of 0.432, although statistically it was a significant association (*P* = 0.006) yet lack of above average agreement prohibited the use of chemiluminescence as a substitute for histopathology. We further observed that the technique is painless, is easy to learn and may help in identifying suspicious lesions missed during visual inspection under incandescent overhead and halogen dental illumination.

One of the drawbacks of the test is, its per patient cost according to socioeconomic status of the country is very high and kit can be used only once per patient. Several benign oral lesions (leukoedema, frictional irritation, lichenoid mucositis) are readily recognized because of their clinical appearance and may be misinterpreted as positive. This may be because the epithelium in these lesions shows hyperkeratinization and/or chronic inflammatory infiltrate, which reflect the chemiluminescent light, more strongly than normal tissue. This was also reiterated by Farah *et al*., who indicated that Vizilite illumination does not discriminate between keratotic, inflammatory, malignant or potentially malignant oral mucosal white lesions, and thus, a high index of suspicion, expert clinical judgment and scalpel biopsy are still essential for proper patient care.\[[@ref31]\]

It is also emphasized that large-scale studies are required to further refine issues related to the selectivity and specificity of the test in correlation with the clinical, cytological and histological features of oral epithelial lesions. In the present study, it was observed that Vizilite is helpful in delineating the borders of the lesions which could be easily missed by conventional visual examination. Few of satellite lesions were also detected which were not recognized on conventional visual examination consistent with the literature.\[[@ref34][@ref19]\]

Diagnostic agreement between toluidine blue and chemiluminescence (Vizilite) was very low with a κ = 0.238 (*P* = 0.060), thus showing that both the tests behaved differently. Sensitivity of Vizilite was greater than toluidine blue in the present study, indicating that it is a more effective test for screening oral cancer, as was equivocal with the finding of Ram and Siar.\[[@ref19]\] However, Mehrotra *et al*. suggested that VELscope was found to have a higher sensitivity when compared with Vizilite.\[[@ref35]\]

Although toluidine blue showed varied results, it was 100% positive for all malignant lesions, and thus, we hypothesize that it can help accelerate the decision to perform a biopsy and assist in the selection of the most suspicious site. Further, this technique is simple, noninvasive and cheap. We also agree with the findings of Epstein *et al*. that chemiluminescence (Vizilite) helps in delineating border of the lesions that extended beyond the clinical borders,\[[@ref36]\] but its per patient cost is high. Thus, both the tests hold their importance as screening devices and can be used in cancer screening procedures.

CONCLUSIONS {#sec1-5}
===========

The present study provides evidence that chemiluminescence is more sensitive in detecting suspicious lesion by enhancing the clinical examination, but it has certain limitations, prohibiting its use in making final diagnosis of the lesions. Toluidine blue gave variable results but was 100% sensitive in detecting malignant lesions, so it might help in the detection of most suspicious site in the lesion for biopsy. To definitively identify the sensitivity and specificity of toluidine blue in detecting such lesions, further studies with more samples are required. Histopathology remains the gold standard for confirmatory diagnosis, whereas both the tests can be used as an adjunct to conventional visual examination.
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